As bevacizumab (Avastin) was demonstrated to improve the response rate and survival of patients with CRC combined with chemotherapy, it became the first approved anti‐VEGF monoclonal antibody by the FDA in 2004.116. This evidence concerns the gene VEGFA and colorectal carcinoma.